Novartis' Neulasta knockoff moves ahead at FDA; Vertex nabs two new Kalydeco approvals in EU;

> Novartis' ($NVS) Sandoz unit closed in on another Amgen ($AMGN) blockbuster with its FDA filing for approval of a biosimilar Neulasta; the Swiss drugmaker launched its Neupogen knockoff Zarxio earlier this year. Release | Report

> Vertex Pharmaceuticals ($VRTX) won two new approvals in Europe for Kalydeco, its cystic fibrosis treatment and blockbuster hopeful. Release

> Isis Pharmaceuticals ($ISIS), a California biotech, is considering changing its name in the wake of the terrorist attacks in Paris. Report

> Sales of a Viagra knockoff in China are swelling, with one company reporting $109 million in revenue for the drug in its first year. Report

> Merck KGaA and Pfizer ($PFE) won FDA breakthrough status for their cancer fighter avelumab, a PD-L1 immunotherapy. Report

And Finally ... Coffee drinkers may be less likely to die from a variety of diseases, including diabetes. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Stinging from a previous trial failure in 2016, AstraZeneca's Brilinta topped solo aspirin in slicing CV risks in heart attack and stroke patients.

Taking over IL-23 inhibitor brazikumab marks a new endeavor for AstraZeneca, as does buying prescription drugs Zenpep and Viokace for Nestlé.